- Home
- ARR vs DAWN Comparison
ARR vs DAWN Comparison
Compare ARR & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARR | DAWN |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ARR | DAWN |
|---|---|---|
| Price | $17.29 | $21.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $18.50 | ★ $24.43 |
| AVG Volume (30 Days) | ★ 2.9M | 1.4M |
| Earning Date | 04-22-2026 | 05-01-2026 |
| Dividend Yield | ★ 16.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | N/A | $55.03 |
| Revenue Next Year | N/A | $28.12 |
| P/E Ratio | $27.18 | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $13.98 | $5.64 |
| 52 Week High | $19.31 | $21.53 |
Technical Indicators
Market Signals| Indicator | ARR | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 80.29 |
| Support Level | $16.99 | $10.30 |
| Resistance Level | $17.74 | N/A |
| Average True Range (ATR) | 0.32 | 0.03 |
| MACD | -0.01 | -0.28 |
| Stochastic Oscillator | 40.69 | 90.91 |
Price Performance
Historical ComparisonAbout ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.